Announcements
- A Red Letter Day for FLC April 21st was a red letter day for the fibrolamellar community. A patient at the Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins University, Baltimore, MD received the initial treatment of the first experimental therapy aimed to directly target the primary molecular cause of fibrolamellar carcinoma (FLC). When Tucker Davis and friends began the Fibrolamellar […]
- TO MEMBERS OF THE FIBROLAMELLAR PATIENT AND CAREGIVING COMMUNITY DURING THIS TIME OF COVID-19 The emerging COVID-19 pandemic has created unprecedented global challenges. We know that for individuals with underlying conditions, including cancer, the situation may seem fraught with uncertainty. We urge patients and caregivers to reach out to their medical care teams for up-to-date information. In addition, if anyone is in a tough financial situation due to the […]
- Opening of FLC Peptide Vaccine Clinical Trial A new clinical trial of an immune therapy for fibrolamellar carcinoma (FLC) is now recruiting subjects at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, MD. The study asks if individuals can mount an effective immune response against FLC by specifically targeting the unique chimeric protein (resulting from a DNAJB1-PRKACA gene […]
- Mark Foundation Aspire Award Granted for Fibrolamellar Research The Fibrolamellar Cancer Foundation (FCF) is proud to announce The Mark Foundation for Cancer Research has awarded their coveted Aspire Award to Dr. Paul Thomas, St. Jude Children’s Research Hospital for fibrolamellar carcinoma immunotherapy research. The Aspire Award (Accelerating Scientific Platforms and Innovative Research),is designed to enable innovative approaches to solving high-impact problems in cancer […]
